Efficacy of tilmicosin in the control of experimentally induced Actinobacillus pleuropneumoniae infection in swine.
The efficacy of tilmicosin administered in the feed to control Actinobacillus pleuropneumoniae infections in pigs was evaluated through a multisite, multitrial study. For each of 6 trials, 48 pigs (stratified by weight and sex) were randomly assigned to 6 to 8 pens. Medicated feed containing tilmicosin (200 g/t) and unmedicated feed were randomly assigned at the pen level and were provided ad libitum from day -7 to trial termination (day 14). Seeder pigs (inoculated intranasally with A. pleuropneumoniae serotype 1 and showing signs of clinical disease) were introduced to each pen on day 0. Rates of death, gross lesions, and culture of A. pleuropneumoniae at necropsy, clinical scores, average daily gain in weight, and average body temperature were compared between the medicated and unmedicated pigs. Compared with the unmedicated pigs, significantly fewer (P < 0.05) pigs given tilmicosin had lesions typical of A. pleuropneumoniae or had A. pleuropneumoniae isolated from their tissues at necropsy. Together with a significant reduction (P < 0.05) in the average percentage of pneumonic lung involvement (both visually and by weight), there were reductions in the numbers of pigs with moderate and severe pneumonic lung lesions and with A. pleuropneumoniae associated mortality. With tilmicosin treatment, the average daily weight gain, daily temperature, abdominal appearance, attitude, and respiration were also significantly better (P < 0.05). The results of this study demonstrate the in vivo effectiveness of tilmicosin (200 g/t) in controlling pleuropneumonia among swine experimentally infected with A. pleuropneumoniae.
Elanco, Division of Eli Lilly Canada Inc., Guelph, Ontario. Paradis_Marie_Anne@Lilly.com
Marie-Anne
MA
Paradis
Gordon H
GH
Vessie
John K
JK
Merrill
C Paul
CP
Dick
Camille
C
Moore
George
G
Charbonneau
M
M
Gottschalk
Janet I
JI
MacInnes
Robert
R
Higgins
K R
KR
Mittal
C
C
Girard
Jeffery J
JJ
Aramini
Jeffrey B
JB
Wilson
D000189:Actinobacillus Infections / Q000188:drug therapy / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae; D000284:Administration, Oral; D000821:Animal Feed; D000818:Animals; D005260:Female; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011792:Quebec; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D018942:Macrolides; C052319:tilmicosin; D015645:Tylosin